Global Cephalosporin Market is expected to thrive at a CAGR of 14.4% during the projected period by 2023
Cephalosporin is a group of semisynthetic, broad-spectrum antibiotics, which is majorly used to treat bacterial infections. It resembles penicillin and hence is used as an alternative for patients who are allergic to penicillin. It is used in the treatment of a variety of clinical conditions, including pneumonia, skin infections, strep throat, staph infections, tonsillitis, bronchitis, otitis media, and gonorrhea. The global cephalosporin market is estimated to reach $1,99,754 million by 2023 from $77,764 million in 2016, growing at a CAGR of 14.4%from 2017 to 2023.
Request for Sample@ https://www.kdmarketinsights.com/sample/5107
The major factors that contribute to the growth of the cephalosporin market include increase in R&D activities to develop highly efficient & safe drugs; upsurge in use of combination therapies; and rise in incidence of pneumonia, tonsillitis, bronchitis, and gonorrhea. Moreover, increased approvals of drugs and growth in awareness about various infections & antibiotic resistance propel the market growth. However, side effects associated with cephalosporin and development of drug-resistant bacterial strains impede the market growth. Conversely, increase in mergers and acquisition among key vendors and development of combination therapies in untapped market are anticipated to provide potential opportunities for the market growth.
The global cephalosporin market is segmented on the basis of generation, type, route of drug administration, application, and region. Based on generation, the market is divided into first-generation cephalosporin, second-generation cephalosporin, third-generation cephalosporin, fourth-generation cephalosporin, and fifth-generation cephalosporin. By type, it is bifurcated into branded and generics.
Depending on route of drug administration, it is classified into injection and oral. The applications covered in the study include respiratory tract infection, skin infection, ear infection, urinary tract infection, sexually transmitted infection, and others. Geographically, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
– The report provides an in-depth analysis of parent market trends, macro-economic indicators, and governing factors.
– This report provides an extensive analysis of the current and emerging market trends and dynamics in the market through 2016–2023 that helps identify the upcoming market opportunities.
– Recent industry trends and developments and the future opportunities are also covered.
– Extensive knowledge about the key market players and their strategies is provided.
– Comprehensive analysis of the various factors that drive and restrain the growth of the market is provided.
Key Market Segments
By Generation
– First-generation Cephalosporin
– Second-generation Cephalosporin
– Third-generation Cephalosporin
– Fourth-generation Cephalosporin
– Fifth-generation Cephalosporin
By Type
– Branded
– Generics
– By Route of Drug Administration
– Injection
– Oral
By Application
– Respiratory Tract Infection
– Skin Infection
– Ear Infection
– Urinary Tract Infection
– Sexually Transmitted Infection
– Others
By Region
– North America
– – U.S.
– – Canada
– – Mexico
– Europe
– – France
– – Germany
– – UK
– – Italy
– – Spain
– – Rest of Europe
– Asia-Pacific
– – Japan
– – China
– – India
– – Australia
– – Rest of Asia-Pacific
– LAMEA
– – Brazil
– – Saudi Arabia
– – South Africa
– – Rest of LAMEA
Key market players
– The key players operating in this market include
– Allergan Plc
– Bristol-Myers Squibb Company
– Lupin Limited
– Sanofi
– Eli Lilly and Company
– F. Hoffmann-La Roche Ltd.
– GlaxoSmithKline Plc
– Merck & Co., Inc.
– Pfizer Inc.
– Teva Pharmaceutical Industries Ltd.
Browse Full Report With TOC@ https://www.kdmarketinsights.com/product/cephalosporin-market
Table of Contents:
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies, 2015-2017
3.2.2.1. Competitive intelligence and strategies of companies
3.3. MARKET DYNAMICS
3.3.1. Drivers
3.3.1.1. Surge in incidence of infectious diseases
3.3.1.2. Increase in R&D activities for the development of combination drugs
3.3.1.3. Rise in funding for the development of antibiotics
3.3.2. Restraints
3.3.2.1. Side effects associated with cephalosporins
3.3.2.2. Antibiotic resistance to cephalosporins
3.3.3. Opportunities
3.3.3.1. Lucrative opportunities in the emerging economies
3.4. MARKET SHARE ANALYSIS, 2016
3.5. PORTERS FIVE FORCES ANALYSIS
3.6. NOVEL MOLECULES IN CEPHALOSPORIN MARKET
3.6.1. CEFTAZIDIME
3.6.2. CEFUROXIME
3.7. COMBINATION THERAPIES IN CEPHALOSPORIN MARKET
CHAPTER 4 CEPHALOSPORIN MARKET, BY GENERATION
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. FIRST-GENERATION CEPHALOSPORIN
4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.3. SECOND-GENERATION CEPHALOSPORIN
4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
4.4. THIRD-GENERATION CEPHALOSPORIN
4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast
4.5. FOURTH-GENERATION CEPHALOSPORIN
4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size and forecast
4.6. FIFTH-GENERATION CEPHALOSPORIN
4.6.1. Key market trends
4.6.2. Growth factors and opportunities
4.6.3. Market size and forecast
CHAPTER 5 CEPHALOSPORIN MARKET, BY TYPE
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. BRANDED CEPHALOSPORIN DRUGS
5.2.1. Market size and forecast
5.3. GENERIC CEPHALOSPORIN DRUGS
5.3.1. Market size and forecast
CHAPTER 6 CEPHALOSPORIN MARKET, BY ROUTE OF DRUG ADMINISTRATION
6.1. OVERVIEW
6.1.1. Market size and forecast
6.2. CEPHALOSHORIN INJECTIONS
6.2.1. Market size and forecast
6.3. ORAL CEPHALOSPORIN DRUGS
6.3.1. Market size and forecast
CHAPTER 7 CEPHALOSPORIN MARKET, BY APPLICATION
7.1. OVERVIEW
7.1.1. Market size and forecast
7.2. RESPIRATORY TRACT INFECTION
7.2.1. Market size and forecast
7.3. SKIN INFECTION
7.3.1. Market size and forecast
7.4. EAR INFECTION
7.4.1. Market size and forecast
7.5. URINARY TRACT INFECTION
7.5.1. Market size and forecast
7.6. SEXUALLY TRANSMITTED INFECTION
7.6.1. Market size and forecast
7.7. OTHERS
7.7.1. Market size and forecast
Continue@.....
Check For Discount@ https://www.kdmarketinsights.com/discount/5107
About Us:
KD Market Insights offers a comprehensive database of syndicated research studies, customized reports, and consulting services. These reports are created to help in making smart, instant and crucial decisions based on extensive and in-depth quantitative information, supported by extensive analysis and industry insights. Our dedicated in-house team ensures the reports satisfy the requirement of the client. We aim at providing value service to our clients. Our reports are backed by extensive industry coverage and is made sure to give importance to the specific needs of our clients. The main idea is to enable our clients to make an informed decision, by keeping them and ourselves up to date with the latest trends in the market.
Contact Us:
KD Market Insights
150 State Street, Albany,
New York, USA 12207
Telephone: +1 (518) 300-1215
Email: sales@kdmarketinsights.com
Website: www.kdmarketinsights.com
Follow us - Facebook, Twitter, Linked In
Comments
Post a Comment